<DOC>
	<DOCNO>NCT02852694</DOCNO>
	<brief_summary>The purpose study compare effectiveness weekly subcutaneously administer Methotrexate maintain relapse-free sustained steroid/Enteral Nutrition -free 1-year remission compare : - daily oral Azathioprine / 6 mercaptopurine low risk paediatric Crohn 's disease - subcutaneously administer adalimumab high risk paediatric Crohn 's disease</brief_summary>
	<brief_title>Reduce Risk Crohn 's Disease Patients</brief_title>
	<detailed_description>In randomize controlled trial PIBDNet ( pediatric inflammatory bowel diseases network ) aim compare follow treatment strategy divide patient two risk group aggressive disease evolution : effectiveness Methotrexate versus Azathioprine / 6 mercaptopurine maintenance remission Crohn 's disease child low risk aggressive disease effectiveness Methotrexate versus adalimumab high risk group . PIBDNet hypothesize Methotrexate superior Azathioprine / 6 mercaptopurine maintain remission Crohn 's disease low risk stratum adalimumab superior Methotrexate high risk stratum .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Children 617 , newonset Crohn Disease diagnose use establish criterion ( 37 , 38 ) , require steroidbased Enteral nutrition base induction therapy 2 . At initial diagnosis , wPCDAI &gt; 40 CRP &gt; 2 time upper limit diagnosis 3. wPCDAI score ( 0120 ) possible inclusion ( patient remission patient active disease ) 4 . Luminal active Crohn Disease ( B1 ) without B2 and/or B3 disease behavior 5 . Initial exposure 5ASA derivate tolerate 6 . Exposure antibiotic tolerate 7 . If one follow criterion present , patient allocate high risk group prior randomization : Complex fistulizing perianal disease Panenteric disease phenotype ( define L3 L4b per Paris classification L3 deep ulcer duodenum , stomach oesophagus ( HP ( helicobacter pylorus ) NSAIDrelated ) ) Severe growth impairment ( height zscore &lt; 2 cross 2 percentile ) likely related CD Significant hypoalbuminemia ( &lt; 30g/l ) , elevate C reactive protein ( CRP ) ( least 2 time normal range ) , wPCDAI &gt; 12.5 despite 3 week optimize induction therapy steroid Exclusive enteral nutrition B2 , B3 B2B3 disease behavior Overall cumulative disease extend â‰¥60 cm 8 . Informed sign consent 1 . Patients wPCDAI &lt; 42,5 initial diagnosis , except CRP &gt; 2 time upper limit 2 . No induction therapy steroid enteral nutrition 3 . Previous therapy IBD ( inflammatory bowel desease ) relate medication induction therapy detail protocol ( except 5ASA ) . 4 . Pregnancy refusal use contraceptive study period pubertal patient ( boys girl ) unless absolute abstinence ( sexual activity ) confirm study visit . Positive pregnancy test throughout study trigger prompt withdrawal patient study . 5 . Lactating mother 6 . Children perianal fistulising disease require surgical therapy ( drainage , seton placement ) 7 . Patients homozygous Thiopurine methyl transferase Thiopurine methyl transferase activity &lt; 6 nmol/h/ml erythrocyte &lt; 9nmol 6MTG ( 6 methylthioguanine/g Hb/h ) , unless qualify high risk patient 8 . Evidence undrained uncontrolled abscess/phlegmon 9 . Contraindication drug use trial ( include intolerance/hypersensitivity allergy either study drug ( thiopurines , methotrexate adalimumab ) ) 10 . Current previous malignancy 11 . Serious comorbidities ( renal insufficiency , hepatitis , respiratory insufficiency ) interfere drug therapy interpretation outcome parameter make unlikely patient finish trial . 12 . Infection mycobacterium tuberculosis 13 . Moderate severe heart failure ( NYHA classe III/IV ) 14 . Oral anticoagulant therapy , antimalaria therapy 15 . Live vaccine exposure ( include yellow fever ) less 3 week prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>